BRPI0812384A2 - Métodos de tratamento, diagnóstico e detecção de distúrbios associados a fgf21 - Google Patents

Métodos de tratamento, diagnóstico e detecção de distúrbios associados a fgf21

Info

Publication number
BRPI0812384A2
BRPI0812384A2 BRPI0812384-5A2A BRPI0812384A BRPI0812384A2 BR PI0812384 A2 BRPI0812384 A2 BR PI0812384A2 BR PI0812384 A BRPI0812384 A BR PI0812384A BR PI0812384 A2 BRPI0812384 A2 BR PI0812384A2
Authority
BR
Brazil
Prior art keywords
treatment
fgf21
diagnostic
methods associated
disease
Prior art date
Application number
BRPI0812384-5A2A
Other languages
English (en)
Inventor
Cheng Liu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0812384A2 publication Critical patent/BRPI0812384A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0812384-5A2A 2007-05-22 2008-05-20 Métodos de tratamento, diagnóstico e detecção de distúrbios associados a fgf21 BRPI0812384A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93951207P 2007-05-22 2007-05-22
PCT/US2008/006481 WO2008153705A2 (en) 2007-05-22 2008-05-20 Methods of treating, diagnosing and detecting fgf21-associated disorders

Publications (1)

Publication Number Publication Date
BRPI0812384A2 true BRPI0812384A2 (pt) 2014-12-02

Family

ID=39739850

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0812384-5A2A BRPI0812384A2 (pt) 2007-05-22 2008-05-20 Métodos de tratamento, diagnóstico e detecção de distúrbios associados a fgf21

Country Status (11)

Country Link
US (1) US20110002845A1 (pt)
EP (1) EP2152737A2 (pt)
JP (1) JP2010529954A (pt)
KR (1) KR20100017169A (pt)
CN (1) CN101679501A (pt)
AU (1) AU2008262450A1 (pt)
BR (1) BRPI0812384A2 (pt)
CA (1) CA2687746A1 (pt)
EA (1) EA200901550A1 (pt)
MX (1) MX2009012625A (pt)
WO (1) WO2008153705A2 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
EA024751B8 (ru) 2008-06-04 2020-01-31 Амген Инк. Мутанты fgf21 и их применение
EP2358749B1 (en) 2008-10-10 2018-07-18 Amgen, Inc Fgf21 mutants and uses thereof
US20120052069A1 (en) 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
SMT202400036T1 (it) 2009-05-05 2024-03-13 Amgen Inc Mutanti fgf21 e loro utilizzi
WO2010139741A1 (en) * 2009-06-04 2010-12-09 Novartis Ag Fgf-21 for treating cancers
AU2010262927A1 (en) 2009-06-17 2012-01-19 Amgen Inc. Chimeric FGF19 polypeptides and uses thereof
JP6016636B2 (ja) * 2009-10-15 2016-10-26 ジェネンテック， インコーポレイテッド 改変したレセプター特異性を持つキメラ線維芽細胞増殖因子
MX2012006397A (es) 2009-12-02 2012-11-30 Amgen Inc PROTEINAS DE ENLACE QUE ENLAZAN A FGFR1C HUMANO, ß-KLOTHO HUMANA Y TANTO FGFR1C HUMANO COMO ß-KLOTHO HUMANA.
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
TWI644675B (zh) * 2010-04-09 2018-12-21 可娜公司 藉由抑制纖維母細胞生長因子２１（ｆｇｆ２１）之天然反義轉錄物以治療ｆｇｆ２１相關疾病
US9517264B2 (en) 2010-04-15 2016-12-13 Amgen Inc. Human FGF receptor and β-Klotho binding proteins
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK4108671T3 (da) 2010-10-01 2025-01-06 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
CN102296110B (zh) * 2011-07-18 2016-08-10 西北农林科技大学 一种检测黄牛fgf21基因单核苷酸多态性的方法
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP2834259A4 (en) 2012-04-02 2016-08-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
MX2017003535A (es) 2014-09-16 2017-10-27 Regeneron Pharma Anticuerpos anti-glucagon y sus usos.
US9955802B2 (en) 2015-04-08 2018-05-01 Fasteners For Retail, Inc. Divider with selectively securable track assembly
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
CN107449715B (zh) * 2016-05-30 2021-01-22 康建胜 活细胞胞内代谢分析仪及其分析方法
EA201991203A1 (ru) 2016-11-17 2019-10-31 Способы лечения ожирения антителами к angptl8
US20200000880A1 (en) * 2017-02-01 2020-01-02 Children's Medical Center Corporation Fgf21 compositions for treatment or prevention of neovascularization of the eye and methods therefor
CN110461863A (zh) * 2017-04-04 2019-11-15 豪夫迈·罗氏有限公司 成纤维细胞活化蛋白(fap)识别的底物及其使用方法
JP7066540B2 (ja) * 2018-06-14 2022-05-13 株式会社日立製作所 デジタルｐｃｒの測定方法および測定装置
CN110279847B (zh) * 2019-05-17 2023-04-14 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 Fgf21在制备促进超长随意皮瓣存活的药物中的应用
CN110257512A (zh) * 2019-05-20 2019-09-20 上海交通大学医学院 用于luminal型和HER2型乳腺癌诊断、治疗及预后的标志物和组合物
CN111420030B (zh) * 2020-05-12 2021-01-29 江南大学 Fgf21在制备用于治疗结直肠癌药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7368100A (en) * 1999-09-10 2001-04-10 Curagen Corporation Fibroblast growth factor polypeptide and nucleic acids encoding same
US6716626B1 (en) * 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
AU1628101A (en) * 1999-11-22 2001-06-04 Millennium Pharmaceuticals, Inc. Jaffa, a novel fibroblast growth factor family member and uses therefor
EP1666493A1 (en) * 2000-06-02 2006-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids ancoding the same
AU2003270424A1 (en) * 2002-09-09 2004-03-29 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7655627B2 (en) * 2004-12-14 2010-02-02 Eli Lilly And Company Muteins of fibroblast growth factor 21
US20080261875A1 (en) * 2005-01-21 2008-10-23 Eli Lilly And Company Method For Treating Cardiovascular Disease
JP2006246823A (ja) * 2005-03-11 2006-09-21 Kyoto Univ 造血因子としてのＦｇｆ２１の使用

Also Published As

Publication number Publication date
WO2008153705A2 (en) 2008-12-18
AU2008262450A1 (en) 2008-12-18
EP2152737A2 (en) 2010-02-17
CN101679501A (zh) 2010-03-24
MX2009012625A (es) 2009-12-07
KR20100017169A (ko) 2010-02-16
EA200901550A1 (ru) 2010-10-29
JP2010529954A (ja) 2010-09-02
WO2008153705A3 (en) 2009-03-05
US20110002845A1 (en) 2011-01-06
CA2687746A1 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
BRPI0812384A2 (pt) Métodos de tratamento, diagnóstico e detecção de distúrbios associados a fgf21
BRPI0917567A2 (pt) tratamento de doença respiratória
BRPI0813212A2 (pt) Métodos de tratamento de doenças e distúrbios mediados por serotonina
BRPI0814889A2 (pt) tratamento com ligantes alfa7-seletivos.
BRPI0813364A2 (pt) Métodos de diagnóstico e tratamento de câncer.
FR2921499B1 (fr) Structure orientable de type catheter ou endoscope
IL212856A (en) Human antibodies against human tissue factor, conjugates and uses thereof
BRPI0807896A2 (pt) Fórceps bipolares não-aderentes.
BRPI0922322A2 (pt) endoscópio com uma porção curvada
BRPI0822633A2 (pt) Desinfetante, e, método de esterilização.
HUE071237T2 (hu) Fabry-kór kezelési lehetõségei
BRPI0923409A2 (pt) cabeça de escova de dentes, e, escova de dentes.
BRPI0815889A2 (pt) Análise do perfil de glicosilação.
BR112012002124A2 (pt) tratamento da doença de crohn com laquinimode.
FR2917962B1 (fr) Electrocardiographe ambulatoire evenementiel.
BRPI0822572A2 (pt) Terapia guiada por imagem de doença moicardial, composição manufaturamento e aplicações
BRPI0820101A2 (pt) Combinação, e, aparelho que cobre a cabeça de estetoscópio
DE602007001361D1 (de) Sphinkterotom mit Zweifachkrümmung
SI2432798T1 (sl) Derivat 17-hidroksi-17-pentafluoretil-estra-4,9(10)-dien-11-arila, postopki izdelave in uporaba pri zdravljenju bolezni
ATE494839T1 (de) Gewebeentnahme
BRPI0810559A2 (pt) Macadores de doenças
FI20075181L (fi) Hammashoitokone, jossa on ohjelmoitavissa olevia toimintoja
DK2173831T3 (da) Brøndbehandling
IL199807A0 (en) Biometric diagnosis
DK1863899T3 (da) Hudbehandlingspræparater

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]